Selected article for: "significant difference and study population"
Author: Khawaja, Fareed; Chemaly, Roy F.
Title: Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies
  • Document date: 2019_7_23
    • ID: 4fx18mlj_28
    Snippet: RSV-specific monoclonal antibodies, such as palivizumab, have also been evaluated for the treatment of RSV infections in HCT recipients and HM patients. Originally, palivizumab was approved for the prevention of RSV infections in neonates and children. Experience with palivizumab as treatment in HCT recipients with RSV is very limited. Several studies showed no survival benefit when comparing palivizumab as adjunctive therapy to ribavirin as mono.....
    Document: RSV-specific monoclonal antibodies, such as palivizumab, have also been evaluated for the treatment of RSV infections in HCT recipients and HM patients. Originally, palivizumab was approved for the prevention of RSV infections in neonates and children. Experience with palivizumab as treatment in HCT recipients with RSV is very limited. Several studies showed no survival benefit when comparing palivizumab as adjunctive therapy to ribavirin as monotherapy for RSV infections in adult HCT recipients. 42, 46, 83, 95, 96 In a recent retrospective study of a mixed population of adult HCT recipients and patients with HM, 97 those treated with palivizumab for RSV infections showed a trend towards better 90-day survival compared to the control group, with mortality rates of 11% compared to 17%, respectively. 97 However, this difference was not statistically significant and recommendations for the routine use of palivizumab in this population of patients cannot be made.

    Search related documents:
    Co phrase search for related documents
    • adjunctive therapy and monoclonal antibody: 1, 2
    • adjunctive therapy and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • control group and HCT recipient: 1
    • control group and mixed population: 1, 2, 3
    • control group and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • control group and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • HCT recipient and mortality rate: 1
    • HM patient and monoclonal antibody: 1
    • HM patient and mortality rate: 1
    • mixed population and mortality rate: 1, 2, 3
    • monoclonal antibody and mortality rate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • monoclonal antibody and palivizumab experience: 1